Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to silence hepatitis b virus

NCT ID NCT03365947

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ARO-HBV in healthy volunteers and people with chronic hepatitis B. The drug uses RNA interference to try to stop the virus from multiplying. The main goal was to check safety and how the body processes the drug, not yet to prove it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ARO-HBV (an RNA interference drug given as a shot)
What this could lead to
If it works, this could lead to a new way to control hepatitis B virus levels, possibly reducing the need for lifelong daily pills.
What could go wrong
This is an early phase 1/2a trial focused on safety and dosing, not yet on effectiveness. Many drugs that look safe in early trials fail to show enough benefit in later, larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS B

Contacts and locations

Locations

  • Research Site 1

    Grafton, Auckland, 1010, New Zealand

  • Research Site 2

    Papatoetoe, Auckland, 2025, New Zealand

  • Research Site 3

    Melbourne, Victoria, 3065, Australia

  • Research Site 4

    Clayton, Victoria, 3168, Australia

  • Research Site 5

    Camperdown, New South Wales, 2050, Australia

  • Research Site 6

    Nedlands, Western Australia, 6009, Australia

  • Research Site 7

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.